Химиотерапия в комплексном лечении больных с первичными злокачественными опухолями головного мозга
Диссертация
Больным с глиобластомой после операции показано проведение лучевой терапии и одновременной химиотерапии темозоломидом с последующей химиотерапией темозоломидом (75 мг/м — во все дни лучевой терапии- 150−200 мг/м2 — дни 1−5, каждые 28 дней, планировалось от 6 курсов при полном ответе на лечение, до 12 курсов и более при контроле опухоли с сохраняющейся контрастируемой частью на МРТ). Может быть… Читать ещё >
Содержание
- Список сокращений
- Глава 1. Обзор литературы
- 1. 1. Эпидемиология и классификация опухолей ЦНС 13 1.1.1 Эпидемиология опухолей ЦНС
- 1. 1. 2. Принципы классификации опухолей ЦНС
- 1. 1. 3. Морфологическая классификация ВОЗ 2007г
- 1. 2. Диагностика опухолей головного мозга
- 1. 2. 1. Основы клинического диагноза
- 1. 2. 2. Современные возможности методов нейровизуализации
- 1. 2. 3. Общие принципы дифференциального диагноза опухолей мозга
- 1. 3. Современные подходы к комплексному лечению первичных злокачественных опухолей головного мозга
- 1. 3. 1. Общие принципы микронейрохирургии
- 1. 3. 2. Лучевая терапия первичных опухолей ЦНС
- 1. 3. 4. Особенности лекарственной терапии опухолей ЦНС
- 1. 4. Биология и современные стандарты лечения злокачественных глиом
- 1. 4. 1. Гистология — основной прогностический фактор глиом
- 1. 4. 2. Комплексное лечение глиобластомы
- 1. 4. 3. Роль таргетных препаратов в лечении глиобластомы
- 1. 5. Первичная лимфома ЦНС у иммунокомпетентных пациентов: диагностика и лечение
- 1. 5. 1. Патоморфология
- 1. 5. 2. Клинические проявления
- 1. 5. 3. Диагностика ПЛЦНС: нейровизуализация
- 1. 5. 4. Лечение первичной лимфомы ЦНС
- 1. 5. 5. Первичная лимфома ЦНС: краткое резюме
- 1. 6. Первичные герминогенные опухоли ЦНС: современные подходы к лечению
- 1. 6. 1. Эпидемиология и теории развития первичных ГКО ЦНС
- 1. 6. 2. Классификация первичных ГКО ЦНС
- 1. 6. 3. Клинические особенности и подходы к лечению первичных ГКО ЦНС
- 1. 7. Медуллобластома у взрослых
- 1. 7. 1. Эпидемиология
- 1. 7. 2. Клиническая картина, нейровизуализационные данные и морфология медуллобластом у взрослых
- 1. 7. 3. Общие данные по лечению медуллобластомы у взрослых и роль химиотерапии
- 1. 1. Эпидемиология и классификация опухолей ЦНС 13 1.1.1 Эпидемиология опухолей ЦНС
Список литературы
- Виноградова И.Н. Хирургическое лечение внутримозговых нейроэкто-дермальных опухолей больших полушарий мозга: Дисс. докт. мед. наук. -М., 1969.
- Голанов A.B. Совершенствование методов диагностики и лечения злокачественных супратенториальных глиом: Доклад на отчетной научной конференции НИИ нейрохирургии им. Н. Н. Бурденко. Москва, 1997.
- Гордеева JI.A., Тимофеева Т. В., Галкина Н. С., Щербакова Е. Я., Панина Т. Н., Мороз Л. В., Котельникова Т. М. Оценка эффективности полихимиотерапии глиальных опухолей головного мозга: Журн. вопр. нейрохирургии им. Н. Н. Бурденко. 5: 18−25. 1987.
- Губкин А. В. Диагностика и лечение первичных лимфатических опухолей головного мозга. // Автореф. дис. канд. мед. наук М., 2004
- Жуков В.Ю. Планирование хирургического доступа при удалении внутримозговых опухолей больших полушарий с использованием функциональной МРТ, навигационных систем и электрофизиологического мониторинга: Дисс. докт. мед. наук / Москва, 2010
- Качков И.А. Комбинированная терапия больных со злокачественными супратенториальными глиомами: Дисс. докт. мед. наук. — М., 1988.
- Корниенко В.Н., Пронин И. Н. Диагностическая нейрорадиология. Второе издание (в 3-х томах). -М.: ИП «Т.А.Алексеева», 2009
- Корниенко В.Н., Пронин И. Н. «Контрастирование в нейрорадиологии» Издательство ИП «Т.А.Алексеева», М. 2010 г
- Круминя Т.А. Полихимиотерапия в комплексном лечении больных с глиальными опухолями головного мозга: Дисс. канд. мед. наук. М., 1986.
- П.Куржупов М. И. «Интраоперационная флюоресцентная диагностика и фотодинамическая терапия у больных с метастатическим поражением головного мозга». Дисс. канд.мед.наук Москва, 2011
- Мазеркина. Эндокринные нарушения после комплексной терапии злокачественных опухолей хиазмально-селлярной области и задней черепной ямки у детей. Дисс. докт.мед.наук Москва, 2006.
- Меликян А.Г. Стереотаксические методы в диагностике и лечении опухолей головного мозга: Дисс. докт. мед. наук. М., 1997.
- Меликян А.Г., Голанов А. В., Касумова С. Ю., Качков И. А., Лобанов С. А., Архипова Н. А. КТ-стереотаксическая биопсия опухолей мозга: Журнал вопросы нейрохирургии им. академика Н. Н. Бурденко. 1991(5): 12−7.
- Неврология. Национальное руководство /Под ред. Гусева Е. И., Коновалова А. Н., Скворцовой В. И., Гехт А. Б. М.: ГЭОТАР-Медиа, 2009
- Онкология: национальное руководство / под ред. Чиссова В. И., Давыдова М. И. — М.: ГЭОТАР-Медиа, 2008.
- Сафаралиев М.М. Хирургическое лечение больных с внутримозговыми опухолями заднелобно-теменно-височной области с интраоперационной идентификацией речевых центров: Дисс. докт. мед. наук / Москва, 2000
- Соснов Ю.Д. Комбинированное лечение злокачественных глиальных опухолей больших полушарий головного мозга: (Хирургическое вмешательство и химиотерапия): Автореф. дис. д-ра мед. наук. Киев, 1981.
- Тоидзе И.В. Хирургическое лечение больных с объемными образованиями в области центральной борозды с интраоперационной идентификацией чувствительных и двигательных зон: Дисс. канд. мед. наук / Москва, 2000
- Ярцев В.В. Особенности кровообращения опухолей астроцитарного ряда больших полушарий головного мозга до и после операционного вмешательства в ангиографическом отображении. Дисс. канд. мед. наук. М., 1988.
- Abacioglu U, Uzel О, Sengoz М, Turkan S, Ober A. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys. 2002 Nov l-54(3):855−60
- Abrey LE, Ben-Porat L, Panageas KS, et al: Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711−5715,2006
- Abrey LE, DeAngelis LM, Yahalom J: Longterm survival in primary CNS lymphoma. J Clin Oncol 16:859−863,1998
- Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: The next step. J Clin Oncol 18:3144−3150,2000
- Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resections on survival and quality of life in patients with supraten-torial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987- 21: 201 206.
- Angelov L., Doolittle N., Kraemer D. et al. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience. // JCO Jul 20 2009: 35 033 509
- Batchelor T, Carson K, O’Neill A, et al: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 9607. J Clin Oncol 21:1044−1049,2003
- Batchelor T, Loeffler JS: Primary CNS lymphoma. J Clin Oncol 24:12 811 288, 2006
- Belozerov VE, Van Meir EG. Inhibitors of hypoxia-inducible factor-1 signaling. Curr Opin Investig Drugs 2006−7:1067−1076.
- Bergers, G. Bone marrow-derived cells in GBM neovascularization. In: Van
- Meir, EG., editor. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1. New York: Humana Press (Springer) — 2009. p. 749−773.
- Blay JY, Conroy T, Chevreau C, et al: Highdose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864−871,1998
- Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004−84:397−405.
- Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007−25:2601−2606.
- Chan AW, Tarbell NJ, Black PM, Louis DN, Frosch MP, Ancukiewicz M, Chapman P, Loeffler JS. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000 Sep-47(3):623−31- discussion 631−2.
- Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three dimensional conformal radiotherapy. J Clin Oncol 2002−20:1635−1642.
- Chan MY, Teo WY, Seow WT, Tan AM. Epidemiology, management and treatment outcome of medulloblastoma in Singapore. Ann Acad Med Singapore. 2007 May-36(5):314−8
- Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005−23:357−361.
- Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005−46:945−952. -
- Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006−47:410−418.
- Cloughesy T., Vredenburgh J. J., Day B., Das A., Friedman H. S. Updated safety and survival of patients with relapsed glioblastoma treated with bevaci-zumab in the BRAIN study. J Clin Oncol 28:15s, 2010 (suppl- abstr 2008)
- Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. tumor activity of rapamy-cin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008−5-8.
- Correa DD, DeAngelis LM, Shi W, et al: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548−555,2004
- Correa DD, Maron L, Harder H, et al: Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol 18:1145−1151,2007
- Crossen JR, Garwood D, Glatstein E, et al: Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol 12:627−642,1994
- Dahlborg SA, Henner WD, Crossen JR, et al: Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2:166−174,1996
- Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009−462:739−744.
- De Witt Hamer P.C., Robles S.G., Zwinderman A.H. et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis — Neurooncology, Nov 2011, Volume 13, Supplement 3
- DeAngelis LM, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93−10. J Clin Oncol 20:4643−4648,2002
- DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992, 10:635−643,
- Doolittle ND, Abrey LE, Shenkier TN, et al: Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: An International Primary CNS Lymphoma Collaborative Group report. Blood 111:1085−1093, 2008
- Doolittle ND, Jahnke K, Belanger R, et al: Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 48:1712−1720,2007
- Ferreri AJ, Abrey LE, Blay JY, et al: Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407−2414,2003
- Ferreri AJ, Blay JY, Reni M, et al: Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266−272,2003
- Feugier P, Virion JM, Tilly H, et al: Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 15: 129−133, 2004
- Fine HA- Dear KB- Loeffler JS- Black PM- Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer- 71(8): 2585−97 1993.
- Fischbach, A.J., Martz, K.L., Nelson, J.S., Griffin, T.W., Chang, C.H., Hor-ton, J., and Nelson, D.F. Long-term survival in treated anaplastic astrocytomas, A report of combined RTOG/ECOG studies. AmJ.Clin.Oncol. 14(5): 365−370, 1991.
- Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999−91:251−260.
- Frost PJ, Laperriere NJ, Wong CS, Milosevic MF, Simpson WJ, Pintilie M. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995 Jul 15- 32(4): 951−60
- Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005- 23:5294−5304.
- Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009- 27: 2052−2058.
- Gavrilovic IT, Hormigo A, Yahalom J, et al: Long-term follow-up of highdose methotrexate based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570−4574, 2006
- Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances in neuroimag-ing techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 2008−21:728−735.
- Glass J, Gruber ML, Cher L, et al: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neuro-surg 81:188−195,1994
- Grant, R., Liang, B.C., Slattery, J., Greenberg, H.S., and Junck, L. Chemotherapy response criteria in malignant glioma. Neurology 48(5): 1336−1340, 1997.
- Gumerlock MK, Belshe BD, Madsen R and Watts C: Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review, J. of Neuro-Oncology, 12: 33−46, 1992.,
- Gumerlock MK, Neuwelt EA: Principles of chemotherapy in brain neoplasia. In: Jellinger K (ed) Therapy of Malignant Brain Tumors. Springer-Verlag, Vienna 277−348,1987.
- Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005−97:880−887.
- Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 2009−14:519−530.
- Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med 2009−87:363−374.
- Harder H, Holtel H, Bromberg JE, et al: Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544−547,2004
- Harisiadis L, Chang CH. Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys. 1977 Sep-0ct-2(9−10):833−41
- Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005−352:997−1003.
- Herrlinger U, Schabet M, Brugger W, et al: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent highdose methotrexate for primary central nervous system lymphoma. Ann Neurol 51:247−252, 2002
- Hu B, Guo P, Bar-Joseph I, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007−26:5577−5586.
- Jahnke K, Doolittle ND, Muldoon LL, et al: Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus 21: E11, 2006
- Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor IT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007−8:610−622.
- James CD, Carlbom E, Nordenskjold M, Collins VP, Cavenee WK. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A 1989−86:2858−2862.
- Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg. 1985−63:155 167.
- Jeremic B- Jovanovic D- Djuric LJ- Jevremovic S- Mijatovic SS: Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with vm-26 and CCNU for malignant gliomas. J.Chemother.- 4(2): 123−6 1992.
- Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factormediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000- 60: 5143−5150.
- Kleihues P, Cavenee WK (eds) (2000) World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, 2000
- Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 2009−15:3617−3623.
- Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009 Mar-92(l):99−105. Epub 2008 Nov 19.
- Lai R, Abrey LE, Rosenblum MK, et al: Treatment-induced leukoencephalo-pathy in primary CNS lymphoma: A clinical and autopsy study. Neurology 62:451−456,2004
- Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985−313:144−147.
- Louis DN et al. Adult medulloblastoma: retrospective analysis. EANO congress, 1994 abs 134
- O.Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO Classification of tumours of the central nervous system. IARC, Lyon, 2007
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug-l 14(2):97−109
- Luna MA, Valenzuela-Tamariz J. Germ-cell tumors of the mediastinum, postmortem findings. Am J Clin Pathol. 1976- 65: 450 454.
- Macdonald DR- Cascino TL- Schold S.C. Jr.- Cairncross J.G.: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8: 1277−80,.
- Malheiros SM, Franco CM, Stavale JN, Santos AJ, Borges LR, Pelaez MP, Ferraz FA, Gabbai AA. Medulloblastoma in adults: a series from Brazil. J Neurooncol. 2002 Dec-60(3):247−53
- Malogolowkin MH, Mahour GH, Krailo M, et al. Germ cell tumors in infancy and childhood: a 45-year experience. Pediatr Pathol. 1990- 10:231 -241.
- Marchi N, Angelov L, Masaryk T, et al: Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 48:732−742, 2007
- Martin M. Laser accelerated radiotherapy: is it on its way to the clinic? J Natl Cancer Inst 2009−101:450−451.
- Mazza C, Pasqualin A, Da Pian R, Donati E. Treatment of medulloblastoma in children: long-term results following surgery, radiotherapy and chemotherapy. ActaNeurochir (Wien). 1981−57(3−4): 163−75
- McAllister LD, Doolittle ND, Guastadisegni PE, et al: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51−60, 2000- discussion 60−61
- Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005−353:2012−2024. PubMed: 16 282 176.
- Muldoon LL, Soussain C, Jahnke K, et al: Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 2007, 25: 2295−2305
- Neuwelt E, Abbott NJ, Abrey L, et al: Strategies to advance translational research into brain barriers. Lancet Neurol 7:84−96,2008I
- Neuwelt EA, Diehl JT, Vu LH, et al: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449−454,1981
- Neuwelt EA, Goldman DL, Dahlborg SA, et al: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580−1590,1991
- Neuwelt EA, Guastadisegni PE, Varallyay P, et al: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26:258−265,2005
- Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009−20:1596−1603. PubMed: 19 491 283.
- Nichols CR, Fox EP. Extragonadal and pediatric germ cell tumors. Hematol Oncol Clin North Am. 1991- 5: 1189 1209.s
- Noda SE, El-Jawahri A, Patel D, Lauten-schlaeger T, Siedow M, Chakravarti A. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol 2009−19:171−178. PubMed: 19 464 632.
- Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008−70:779−787. PubMed: 18 316 689.
- Novotny A, Stummer W. 5-Aminolevulinic acid and the blood-brain barrier -a review. Med Laser Appl 2003- 18(1): 360.
- Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008 Nov-65(l l):1419−24
- Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009−15:220−231.
- Panageas KS, Elkin EB, DeAngelis LM, et al: Trends in survival from primary Central nervous system lymphoma, 1975−1999: A population-based analysis. Cancer 104:2466−2472,2005
- Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008−321:1807−1812.
- Pels H, Schmidt-Wolf IG, Glasmacher A, et al: Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489−4495, 2003
- Prados MD, Warnick RE, Wara WM, Larson DA, Lamborn K, Wilson CB.
- Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995 Jul 15−32(4):1145−1152
- Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004−2007. CBTRUS Statistical Report Tables 2011 / http://www.cbtrus.org/2007−2008/2007−20 081 .html
- Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adult with recurrent glioblastoma. J Neurooncol 2010−96:219−230.
- Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide av?3 and av?5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011 Mar-7(3):339−54.
- Robins HI, Wen PY, Chang SM, et al. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (NABTC 04−02). J Clin Oncol 2007−25:2057. PubMed: 17 513 810.
- Rodriguez, L.A., Prados, M., Silver, P., and Levin, V.A. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64(12):2420−2423,1989.
- Roman-Goldstein S, Mitchell P, Crossen JR, et al: MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. AJNR Am J Neuroradiol 16:543−553, 1995
- Rousseau A, Mokhtari K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system what has changed? Curr Opin Neurol. 2008 Dec- 21(6):720−7
- Rubenstein JL, Combs D, Rosenberg J, et al: Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood 101:466−468, 2003
- Sano K. Pathogenesis of intracranial germ cell tumors reconsidered. J Neuro-surg. 1999- 90: 258−264.
- Sawamura Y and de Tribolet N: Non-surgical treatment of brain tumors. In Symon L., et al., eds. Advances and Technical standarts in Neurosurgery. New York: Springer-Verlag, 1990.
- Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999−84:10−18.
- Shah GD, Yahalom J, Correa DD, et al: Combined immunochemotherapy with reduced whole brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730−4735,2007
- Shoup TM, Olson J, Hoffman JM, et al. Synthesis and evaluation of 18 °F.1-amino-3-fluorocyclobutane-l-carboxylic acid to image brain tumors. J Nucl Med 1999−40:331−338. [PubMed: 10 025 843]
- Smith JR, Rosenbaum JT, Wilson DJ, et al: Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709−1716,2002
- Stieber VW, Mehta MP. Advances in radiation therapy for brain tumors. Neurol Clin 2007−25:1005−1033. PubMed: 17 964 024.
- Stokoe, D.- Furnari, FB. The PTEN/PI3 kinase pathway in human glioma. In: Van Meir, EG., editor. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1. New York: Humana Press (Springer) — 2009. p. 315−357.
- Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.' Science 2007−318:287−290. PubMed: 17 872 411.
- Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000−93(6):1003−13.
- Treatment of Cancer Brain Tumour and Radiation Oncology Groups- National Cancer Institute of Canada Clinical Trials Group. Lancet Oncol. 2009 May- 10(5):459−66.
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005−352:987−996.
- Takei Y, Pearl GS. Ultrastructural study of intracranial yolk sac tumor: with special reference to the oncologic phylogeny of germ cell tumors. Cancer. 1981−48:2038−2046.
- Teilum G. Classification of endodermal sinus tumour (mesoblastomavitel-linum) and so-called «embryonal carcinoma» of the ovary. Acta Pathol Microbiol Scand. 1965−64:407−429.
- Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (la-patinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010−65:353−361.i
- Tomita T, McLone DG. Medulloblastoma in childhood: results of radical resection and low-dose neuraxis radiation therapy. J Neurosurg. 1986 Feb-64(2):238−42
- Tuettenberg J, Grobholz R, Seiz M, et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res
- Clin Oncol 2009−135:1239−1244.i
- Verhaak RGW, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 2010- 17:98 110.
- Villano et al.: Pineal germ-cell tumors. Neuro-Oncology, April 2008 130
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD,
- Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15−13(4):1253−9.
- Walker MD, Alexander E, Hunt WE, et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333, 1978
- Walker MD, Green SB, Byar DP et al.: Randomised comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303: 1323−1329,1980
- Wallner KE, Pruitt A. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys, 16: 1405 -1409,1989
- Watne, K., Nome, O., Hager, B., and Hirschberg, H. Pre-radiation chemotherapy in glioma patients with poor prognostic factors. J.Neurooncol. 13(3): 261−264, 1992.
- Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997 Jan-8(l):92−7.
- Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008−359:492−507.
- Wen.PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99−08. Clin Cancer Res 2006−12:4899−4907.
- Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003−5:79−88.
- Westphal M, Lamszus K. Other experimental therapies for glioma. Recent Results Cancer Res. 2009−171:155−64.
- Wick: W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 2002 Mar 15−62(6):1915−9.
- Wilson CB: Reoperation for primary tumors. Seminar Oncology 2: 19, 1975.
- Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug- 17(8):2572−8
- Yin, S.- Van Meir, EG. p53 pathway alterations in brain tumors. In: Van Meir, EG., editor. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1. New York: Humana Press (Springer) — 2009. p. 283−314.
- Young B, Oldfield EH, Markesberry WR et al: Reoperation for glioblastoma. J Neurosurg 55: 917, 1981.
- Yung WK. Temozolomide in malignant gliomas. Semin Oncol. 2000 Jun-27(3 Suppl 6):27−34.
- Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. Science 2009−324:261−265.
- Zheng H, Ying H, Yan H, et al. p53 and PTEN control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008−455:1129−1133.